Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
about
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyCIViC databaseHeterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.
P2860
Q26744284-FCB2F680-6D3B-40BC-89A9-B48A9CF1C67FQ27612411-2D3C5BEC-2BD5-4571-BEDC-32FFF983ABDDQ27853391-8505CF8E-9443-434F-A783-8DFF87B2F380Q37094986-1E6DFD9B-9175-4406-85F4-DE3ED37E7A52Q38767492-84B73F2D-6537-4759-90AD-6AFA65C48293Q38931077-5C05061E-28B0-434F-B3CC-02CE814BB832Q54979668-EDA1C5C4-EF85-4422-969B-77B5F46C83E4
P2860
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Clinical and in vivo evidence ...... as are sensitive to erlotinib.
@ast
Clinical and in vivo evidence ...... as are sensitive to erlotinib.
@en
Clinical and in vivo evidence ...... as are sensitive to erlotinib.
@nl
type
label
Clinical and in vivo evidence ...... as are sensitive to erlotinib.
@ast
Clinical and in vivo evidence ...... as are sensitive to erlotinib.
@en
Clinical and in vivo evidence ...... as are sensitive to erlotinib.
@nl
altLabel
Clinical and in vivo Evidence ...... mas Are Sensitive to Erlotinib
@en
prefLabel
Clinical and in vivo evidence ...... as are sensitive to erlotinib.
@ast
Clinical and in vivo evidence ...... as are sensitive to erlotinib.
@en
Clinical and in vivo evidence ...... as are sensitive to erlotinib.
@nl
P2093
P2860
P3181
P1476
Clinical and in vivo evidence ...... mas are sensitive to erlotinib
@en
P2093
Boris Reva
Maria E Arcila
Matthew D Hellmann
Naiyer A Rizvi
P2860
P3181
P356
10.1097/JTO.0000000000000221
P577
2014-10-01T00:00:00Z